128 related articles for article (PubMed ID: 8204273)
1. Serum tumor markers for detection of bone metastasis in breast cancer patients.
Aydiner A; Topuz E; Dişçi R; Yasasever V; Dinçer M; Dinçol K; Bilge N
Acta Oncol; 1994; 33(2):181-6. PubMed ID: 8204273
[TBL] [Abstract][Full Text] [Related]
2. Multivariate analysis of serum tumor markers for diagnosis of skeletal metastases.
Shinozaki T; Chigira M; Kato K
Cancer; 1992 Jan; 69(1):108-12. PubMed ID: 1370133
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
4. Serum tumor markers for detection of bone metastases in patients with lung neuroendocrine neoplasms".
Rosiek V; Wójcik-Giertuga M; Kos-Kudła B
Cancer Treat Res Commun; 2022; 31():100533. PubMed ID: 35202905
[TBL] [Abstract][Full Text] [Related]
5. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena.
Yasasever V; Dinçer M; Camlica H; Karaloğlu D; Dalay N
Clin Biochem; 1997 Feb; 30(1):53-6. PubMed ID: 9056110
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of serum tumor markers in skeletal metastasis of carcinomas.
Chigira M; Shinozaki T
Arch Orthop Trauma Surg; 1990; 109(5):247-51. PubMed ID: 1702981
[TBL] [Abstract][Full Text] [Related]
7. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
Gedik GK; Kiratli PO; Tascioglu B; Aras T
Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
[TBL] [Abstract][Full Text] [Related]
8. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
[TBL] [Abstract][Full Text] [Related]
9. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis of skeletal metastases by serum tumor markers].
Shinozaki T; Chigira M
Nihon Seikeigeka Gakkai Zasshi; 1991 Aug; 65(8):441-6. PubMed ID: 1720162
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques.
Zanco P; Rota G; Sportiello V; Borsato N; Ferlin G
Int J Biol Markers; 1989; 4(2):103-5. PubMed ID: 2768888
[TBL] [Abstract][Full Text] [Related]
12. [Carcino-embryonic antigen and beta 2 microglobulin in malignant bone diseases. 61 cases (author's transl)].
Trèves R; Clément A; Desproges-Gotteron R; Olivier JP; Beck C
Nouv Presse Med; 1982 Jan; 11(1):21-4. PubMed ID: 6173840
[TBL] [Abstract][Full Text] [Related]
13. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
Yildiz M; Oral B; Bozkurt M; Cobaner A
Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
[TBL] [Abstract][Full Text] [Related]
14. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3.
van Dalen A
Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693
[TBL] [Abstract][Full Text] [Related]
15. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
17. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
[TBL] [Abstract][Full Text] [Related]
18. Serological markers for metastatic breast cancer.
Ng JS; Sturgeon CM; Seth J; Paterson GM; Roulston JE; Leonard RC
Dis Markers; 1993 Dec; 11(5-6):217-23. PubMed ID: 8082311
[TBL] [Abstract][Full Text] [Related]
19. Serum tumor markers in skeletal metastasis.
Tsukushi S; Katagiri H; Kataoka T; Nishida Y; Ishiguro N
Jpn J Clin Oncol; 2006 Jul; 36(7):439-44. PubMed ID: 16815865
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of tumor markers in breast cancer patients].
Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
